The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity
Abstract
Programmed cell death 4 (Pdcd4), originally identified as an inhibitor of murine cellular transformation, inhibits protein synthesis by directly interacting with eukaryotic initiation factor 4A (eIF4A) of the translation initiation complex. The relevance of Pdcd4 to a broad range of human cancers derived from multiple tissue sites is unknown. Protein expression patterns from the National Cancer Institute drug-screening panel of 60 human cancer cells (NCI60) were analyzed by Western blot methods and revealed frequent reduction of Pdcd4 protein levels in renal-, lung-, and glia-derived tumors. Greater than mean Pdcd4 protein levels correlated with the antitumor activity of geldanamycin and tamoxifen. Stable expression of antisense PDCD4 significantly reduced the sensitivity of MCF-7 breast cancer cells to geldanamycin and to tamoxifen. Sensitivity to geldanamycin significantly increased in UO-31 renal cancer cells expressing sense PDCD4 cDNA. Increased geldanamycin sensitivity was accompanied by enhanced cell cycle arrest and apoptosis. One primary mode of inactivation of Pdcd4 in human cancers appears to involve down-regulated expression, and this down-regulation causes a decreased sensitivity to geldanamycin cytotoxicity. Thus, up-regulating Pdcd4 expression may be promising for geldanamycin-based combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that PDCD4 upregulation sensitizes tumor cells to anti-tumor drugs such as cisplatin [104], gemcitabine [102], geldanamycin and tamoxifen [105].”
From Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions (2019) · cites this paper as [105]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Monks, A. P., Scudiero, D. A., Skehan, P., Shoemaker, R. H., Paull, K. D., Vistica, D. T., Hose, C. D., Langley, J. W., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,305
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,858
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,765
Regulation of matrix metalloproteinase expression in tumor invasion
Westermarck, J. K., & Kähäri, V. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.781 · Cited by 1,494
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M. C., Smith, L. H., Lee, J. K., Tanabe, L. K., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A. P., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 970
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 778
Research works printed but not linked: 1
- Matsuhashi S, Yoshinaga H, Yatsuki H, Tsugita A, Hori K. Isolation of a novel gene from a human cell line with Pr-28 MAb which recognizes a nuclear antigen involved in the cell cycle. Res Commun Biochem Cell Mol Biol, 1997;1:109–20.
Cited by
Sorted by citations
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707224200 · Cited by 1,141
miR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987
Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., Calin, G. A., Volinia, S., Liu, C., Scarpa, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5194 · Cited by 775
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711
Self-citationMicroRNA 29b functions in acute myeloid leukemia
Garzon, R., Heaphy, C. E. A., Havelange, V., Fabbri, M., Volinia, S., Tsao, T., Zanesi, N., Kornblau, S. M., Marcucci, G., Calin, G. A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211938 · Cited by 473
Bordeleau, M.-È., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H., Brem, B., Greger, H., Lowe, S. W., Porco, J. A. J., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 335
The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation
Lankat–Buttgereit, B., & Göke, R. (2009) · Biology of the Cell · doi:10.1042/bc20080191 · Cited by 315
MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma
Hiyoshi, Y., Kamohara, H., Karashima, R., Sato, N., Imamura, Y., Nagai, Y., Yoshida, N., Toyama, E., Hayashi, N., Watanabe, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2545 · Cited by 269
Zhang, H., Ozaki, I., Mizuta, T., Hamajima, H., Yasutake, T., Eguchi, Y., Ideguchi, H., Yamamoto, K., & Matsuhashi, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209634 · Cited by 247
Cisplatin-Based Chemotherapy of Human Cancers.
Brown, A. M., Kumar, S., & Tchounwou, P. B. (2019) · PubMed · Cited by 229
Epidermal Expression of the Translation Inhibitor Programmed Cell Death 4 Suppresses Tumorigenesis
Jansen, A. P., Camalier, C. E., & Colburn, N. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2119 · Cited by 212
Self-citationYang, H.-S., Matthews, C. P., Clair, T., Wang, Q., Baker, A. R., Li, C.-C. H., Tan, T.-H., & Colburn, N. H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1297-1306.2006 · Cited by 202
Self-citationTomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Tomokuni, A., Kobayashi, S., Marubashi, S., Takeda, Y., Tanemura, M., Umeshita, K., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605958 · Cited by 178
Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 4
Hilliard, A., Hilliard, B., Zheng, S.-J., Sun, H., Miwa, T., Song, W., Göke, R., & Chen, Y. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8095 · Cited by 167
PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains
Suzuki, C., Garces, R. G., Edmonds, K. A., Hiller, S., Hyberts, S. G., Marintchev, A., & Wagner, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712235105 · Cited by 165
Leupold, J. H., Yang, H.-S., Colburn, N. H., Asangani, I., Post, S., & Allgayer, H. (2007) · Oncogene · doi:10.1038/sj.onc.1210234 · Cited by 163
Self-citationAfonja, O., Juste, D., Das, S., Matsuhashi, S., & Samuels, H. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207983 · Cited by 154
Translation Inhibitor Pdcd4 Is Targeted for Degradation during Tumor Promotion
Schmid, T., Jansen, A. P., Baker, A. R., Hegamyer, G., Hagan, J. P., & Colburn, N. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1719 · Cited by 151
Self-citationThe biological and therapeutic relevance of mRNA translation in cancer
Blagden, S. P., & Willis, A. E. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.16 · Cited by 158
Liu, X., Zhang, Z., Sun, L. J., Chai, N., Tang, S., Jin, J., Hu, H., Nie, Y., Wang, X., Wu, K., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr213 · Cited by 149
Wang, Q., Sun, Z., & Yang, H. (2007) · Oncogene · doi:10.1038/sj.onc.1210793 · Cited by 149
Wang, Z. (2012) · Oncology Reports · doi:10.3892/or.2012.1682 · Cited by 154
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions
Matsuhashi, S., Manirujjaman, M., Hamajima, H., & Ozaki, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092304 · Cited by 143
Reis, P. P., Tomenson, M., Cervigne, N. K., Machado, J., Jurišica, I., Pintilie, M., Sukhai, M. A., Perez‐Ordoñez, B., Grenman, R. A., Gilbert, R. W., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-238 · Cited by 141
SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination
Li, C., Du, L., Ren, Y., Liu, X., Jiao, Q., Cui, D., Wen, M., Wang, C., Wei, G., Wang, Y., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1069-3 · Cited by 133
Structural basis for translational inhibition by the tumour suppressor Pdcd4
Loh, P. G., Yang, H., Walsh, M. A., Wang, Q., Wang, X., Cheng, Z., Liu, D. X., & Song, H. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.278 · Cited by 128
Pdcd4, a colon cancer prognostic that is regulated by a microRNA
Allgayer, H. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.09.001 · Cited by 123
Crystal structure of the eIF4A–PDCD4 complex
Chang, J. H., Cho, Y. H., Sohn, S. Y., Choi, J. M., Kim, A., Kim, Y. C., Jang, S. K., & Cho, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808275106 · Cited by 120
Liwak, U., Thakor, N., Jordan, L. E., Roy, R., Lewis, S. M., Pardo, O. E., Seckl, M., & Holcik, M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06317-11 · Cited by 106
Frequent loss of PDCD4 expression in human glioma: Possible role in the tumorigenesis of glioma
Gao, F., Zhang, P., Zhou, C., Li, J., Wang, Q., Zhu, F., Ma, C., Sun, W., & Zhang, L. (2007) · Oncology Reports · doi:10.3892/or.17.1.123 · Cited by 100
Dysregulation of protein synthesis and disease
Quesne, J. P. C. L., Spriggs, K. A., Bushell, M., & Willis, A. E. (2009) · The Journal of Pathology · doi:10.1002/path.2627 · Cited by 102
Özpolat, B., Akar, U., Steiner, M., Zorrilla, I. R., Tírado-Gómez, M., Colburn, N. H., Danilenko, M., Kornblau, S. M., & Berestein, G. L. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0125 · Cited by 94
Self-citationBhatti, I. K., Lee, A., James, V. H., Hall, R. I., Lund, J. N., Tufarelli, C., Lobo, D. N., & Larvin, M. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1381-x · Cited by 91
Nieves-Alicea, R., Colburn, N. H., Simeone, A., & Tari, A. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9993-5 · Cited by 85
Self-citationSynthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors
Liu, T., Nair, S. J., Lescarbeau, A., Belani, J. D., Peluso, S., Conley, J., Tillotson, B. P., O’Hearn, P. J., Smith, S. A., Slocum, K. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011542 · Cited by 86
Wang, D., Sun, X., Wei, Y., Liang, H., Yuan, M., Jin, F., Chen, X., Liu, Y., Zhang, C.-Y., Li, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1254 · Cited by 82
Alterations in the expression of PDCD4 in ductal carcinoma of the breast
Wen, Y., Shi, X., Chiriboga, L. A., Matsahashi, S., Yee, H. T., & Afonja, O. (2007) · Oncology Reports · doi:10.3892/or.18.6.1387 · Cited by 81
Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
Wei, N., Liu, S. S., Leung, T. H., Tam, K., Liao, X. Y., Cheung, A., Chan, K. K. L., & Ngan, H. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-70 · Cited by 80
Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies
Bilanges, B., & Stokoe, D. (2007) · Oncogene · doi:10.1038/sj.onc.1210431 · Cited by 81
Structural Basis for Inhibition of Translation by the Tumor Suppressor Pdcd4
LaRonde-LeBlanc, N. A., Santhanam, A. N., Baker, A. R., Wlodawer, A., & Colburn, N. H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00867-06 · Cited by 76
Self-citationRen, W., Wang, X., Gao, L., Li, S., Yan, X., Zhang, J., Huang, C. Y., Zhang, Y., & Zhi, K. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-1976-8 · Cited by 72
siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression
Bitomsky, N., Wethkamp, N., Marikkannu, R., & Klempnauer, K.-H. (2008) · Oncogene · doi:10.1038/onc.2008.115 · Cited by 75
Lin, C., Robert, F., Sukarieh, R., Michnick, S. W., & Pelletier, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4072 · Cited by 69
microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells
Li, H., Xu, H., Shen, H., & Li, H. (2013) · Oncology Letters · doi:10.3892/ol.2013.1644 · Cited by 68
Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion
Santhanam, A. N., Baker, A. R., Hegamyer, G., Kirschmann, D. A., & Colburn, N. H. (2010) · Oncogene · doi:10.1038/onc.2010.158 · Cited by 67
Self-citationGao, F., Wang, X., Zhu, F., Wang, Q., Zhang, X., Guo, C., Zhou, C., Ma, C., Sun, W., Zhang, Y., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00497.x · Cited by 66
Xia, Q., Kong, X.-T., Zhang, G., Hou, X.-J., Qiang, H., & Zhong, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.181 · Cited by 64
Blees, J. S., Bokesch, H. R., Rübsamen, D., Schulz, K. L., Milke, L., Bajer, M. M., Gustafson, K. R., Henrich, C. J., McMahon, J. B., Colburn, N. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046567 · Cited by 63
Self-citationMeng, H., Wang, K., Chen, X., Guan, X., Hu, L., Xiong, G., Li, J., & Bai, Y. (2015) · PubMed · Cited by 59
Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
Wei, N., Liu, S. S., Chan, K. K. L., & Ngan, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030311 · Cited by 59
PDCD4 inhibits the malignant phenotype of ovarian cancer cells
Wei, Z., Zhang, X., Wang, X., Gao, F., Zhou, C., Zhu, F., Wang, Q., Gao, Q., Ma, C., Sun, W., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01210.x · Cited by 53
Bera, A., Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Abboud, H. E., & Choudhury, G. G. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.06.022 · Cited by 54
Wang, Y., & O'Doherty, G. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja404401f · Cited by 50
Lu, P., Sun, H., Zhang, L., Hou, H., Zhang, L., Zhao, F., Ge, C., Yao, M., Wang, T., & Li, J. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00055 · Cited by 50
Targeting translation: eIF4E as an emerging anticancer drug target
Lu, C., Makala, L., Wu, D., & Cai, Y. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.20 · Cited by 50
Yu, K., Ganesan, K., Miller, L. D., & Tan, P. B. O. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1530 · Cited by 45
Waters, L. C., Veverka, V., Böhm, M., Schmedt, T., Choong, P. T., Muskett, F. W., Klempnauer, K.-H., & Carr, M. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210305 · Cited by 49
Programmed cell death 4 protein in esophageal cancer
Rugge (2010) · Oncology Reports · doi:10.3892/or_00000838 · Cited by 45
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms
Zatelli, M. C., Grossrubatscher, E. M., Guadagno, E., Sciammarella, C., Faggiano, A., & Colao, A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0091 · Cited by 44
Li, Y., Wang, X., Wang, X., Wan, L., Liu, Y., Shi, Y., Zhang, L., Fang, Z., & Wei, Z. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy052 · Cited by 42
Fawzy, M. S., Toraih, E. A., Ibrahiem, A. T., Abdeldayem, H., Mohamed, A. O., & Abdel‐Daim, M. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187310 · Cited by 41
Silibinin inhibits translation initiation: implications for anticancer therapy
Lin, C., Sukarieh, R., & Pelletier, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1152 · Cited by 40
Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation
Schmid, T., Bajer, M. M., Blees, J. S., Eifler, L. K., Milke, L., Rübsamen, D., Schulz, K., Weigert, A., Baker, A. R., Colburn, N. H., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr131 · Cited by 39
Self-citationZhang, X., Wang, X., Song, X., Liu, C., Shi, Y., Wang, Y., Afonja, O., Ma, C., Chen, Y. H., & Zhang, L. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01664.x · Cited by 41
Matsuhashi, S., NARISAWA, Y., Ozaki, I., & Mizuta, T. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00531.x · Cited by 41
Sun, Z., Li, S., Kaufmann, A. M., & Albers, A. E. (2014) · Oncology Reports · doi:10.3892/or.2014.3456 · Cited by 39
Waters, L. C., Strong, S. L., Ferlemann, E., Oka, O., Muskett, F. W., Veverka, V., Banerjee, S., Schmedt, T., Henry, A. J., Klempnauer, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.166157 · Cited by 40
Cuesta, R., & Holz, M. K. (2016) · Oncotarget · doi:10.18632/oncotarget.8375 · Cited by 37
Dissecting the Roles of PDCD4 in Breast Cancer
Cai, Q., Yang, H., Li, Y., & Zhu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855807 · Cited by 39
The Regulatory Role of Non-coding RNAs on Programmed Cell Death Four in Inflammation and Cancer
Zhao, M., Zhu, N., Hao, F., Song, Y., Wang, Z., Ni, Y., & Ding, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00919 · Cited by 37
Ma, G., Zhang, H., Dong, M., Zheng, X., Ozaki, I., Matsuhashi, S., & Guo, K. (2013) · Tumor Biology · doi:10.1007/s13277-013-0975-9 · Cited by 34
Pdcd4 protein and mRNA level alterations do not correlate in human lung tumors
Калиниченко, С. В., Kopantzev, E. P., Korobko, E. V., Palgova, I. V., Эдуардовна, З. Л., Mv, B., Petrov, A. N., Frank, G. A., Sverdlov, E. D., & Korobko, I. V. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.03.022 · Cited by 33
Wang, W., Zhang, H., Wang, H., Sun, Y.-G., Peng, Z.-H., Zhou, G., Yang, S., Wang, R., & Fang, D.-C. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256368 · Cited by 33
Mohammadi, C., Khoei, S. G., Hosseini, N. F., Mohammadi, Y., & Najafi, R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103183 · Cited by 34
How metformin affects various malignancies by means of microRNAs: a brief review
Alimoradi, N., Firouzabadi, N., & Fatehi, R. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01921-z · Cited by 29
Wei, C., Song, H., Sun, X., Li, D., Song, J., Hua, K., & Fang, L. (2015) · Oncology Reports · doi:10.3892/or.2015.3971 · Cited by 29
Xu, H., Dephoure, N., Sun, H., Zhang, H., Fan, F., Liu, J., Ning, X., Dai, S., Liu, B., Gao, M., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00004 · Cited by 29
Wang, W., Zhao, J., Wang, H., Yonggang, S., Peng, Z., Zhou, G., Fan, L., Wang, X., Yang, S., Wang, R., et al. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.05.027 · Cited by 28
Lankat–Buttgereit, B., Lenschen, B., Schmidt, H., & Göke, R. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0153-x · Cited by 28
Cuccarese, M. F., Wang, Y., Beuning, P. J., & O'Doherty, G. A. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4005039 · Cited by 26
Lankat–Buttgereit, B., Müller, S., Schmidt, H., Parhofer, K. G., Gress, T. M., & Göke, R. (2008) · Biology of the Cell · doi:10.1042/bc20080052 · Cited by 25
Total Synthesis of (+)-Cryptocaryol A Using a Prins Cyclization/Reductive Cleavage Sequence
Brun, E., Bellosta, V., & Cossy, J. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01323 · Cited by 24
Leupold, J. H., Asangani, I. A., Mudduluru, G., & Allgayer, H. (2012) · Bioscience Reports · doi:10.1042/bsr20110045 · Cited by 23
Yin, F., LIU, L., Liu, X., LI, G., Zheng, L. X., Li, D., Wang, Q., Zhang, W., & Li, L. (2014) · Oncology Reports · doi:10.3892/or.2014.3175 · Cited by 23
IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas
Ramkumar, H. L., Shen, D. F., Tuo, J., Braziel, R. M., Coupland, S. E., Smith, J. R., & Chan, C. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2037-1 · Cited by 22
Zhao, J., Cao, J., Zhou, L., Du, Y., Zhang, X., Yang, B., Gao, Y., Wang, Y., Ma, N., & Yang, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.9307 · Cited by 22
Zhu, W., Li, Y., & Gao, L. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3252 · Cited by 19
Hu, L., Liang, Y., Wu, K., Wang, C., Zhang, T., Peng, R., & Zou, F. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4292 · Cited by 18
Blees, J. S., Schmid, T., Thomas, C. L., Baker, A. R., Benson, L. C., Evans, J. R., Goncharova, E. I., Colburn, N. H., McMahon, J. B., & Henrich, C. J. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109351028 · Cited by 18
Self-citationZhang, Z., Jin, A., & Yan, D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7963 · Cited by 16
Bredenkamp, A., Wegener, M., Hummel, S., Häring, A. P., & Kirsch, S. F. (2015) · Chemical Communications · doi:10.1039/c5cc09328g · Cited by 16
Interaction of Pdcd4 with eIF4E inhibits the metastatic potential of hepatocellular carcinoma
Jiang, Y., Zhang, S. H., Han, G. Q., & Qin, C. Y. (2010) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2010.01.015 · Cited by 14
Hwang, S., Minai‐Tehrani, A., Lim, H.-T., Shin, J., An, G.-H., Lee, K.-H., Park, K., Kim, Y.-S., Beck, G. R., Yang, H., et al. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0778 · Cited by 13
Pdcd4 tumor suppressor: Properties, functions, and possible applications in oncology
Вихрева, П. Н., Shepelev, M. V., Korobko, E. V., & Korobko, I. V. (2010) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416810020011 · Cited by 15
mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells
Vikhreva, P. N., Shepelev, M. V., & Korobko, I. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.12.001 · Cited by 13
Gedawy, G. A. E., Obada, M., Kelani, A., El‐Said, H., & Ghanayem, N. M. (2016) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2016.04.007 · Cited by 15
Ferris, W. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903374 · Cited by 11
Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis
Madera, S., Chervo, M. F., Chiauzzi, V. A., Pereyra, M. G., Venturutti, L., Izzo, F., Deamicis, A. R., Guzmán, P., Dupont, A., Roa, J. C., et al. (2020) · Hormones and Cancer · doi:10.1007/s12672-020-00392-4 · Cited by 13
Tran, T. T. T., Rane, C. K., Zito, C. R., Weiss, S. A., Jessel, S., Lucca, L. E., Lu, B. Y., Oria, V. O., Adeniran, A., Chiang, V., et al. (2021) · Cancers · doi:10.3390/cancers13051049 · Cited by 14
Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma
Fischer, N., Göke, F., Splittstößer, V., Lankat–Buttgereit, B., Müller, S. C., & Ellinger, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.035 · Cited by 11
Metadata
- Authors
- Jansen, A. P., Camalier, C. E., Stark, C., & Colburn, N. H.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- Venue
- Molecular Cancer Therapeutics
- Published
- 2004-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 103-110
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2257484201
- Cited by
- 132
- References
- 46
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 9
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PDCD4, eIF4A, translation initiation, drug sensitivity, geldanamycin, tamoxifen, kidney cancer, breast cancer, apoptosis, cell cycle arrest, combination therapy, tumor suppressor
- MeSH terms
- Antineoplastic Agents, Cell Division, Drug Screening Assays, Antitumor, Humans, Kidney Neoplasms, Mitosis, Neoplasms, Prognosis, Quinones, RNA, Messenger, Tamoxifen, Retinoblastoma Protein, G2 Phase, Benzoquinones, Tacrolimus, RNA-Binding Proteins, Cell Line, Tumor, Lactams, Macrocyclic, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review